The FDA approved Steglatro (ertugliflozin) as a monotherapy in conjunction with diet and exercise to improve glycaemic control in adults with type 2 diabetes. Meanwhile Steglujan (ertugliflozin ...

NICE has recommended that England’s NHS should routinely fund Merck, Sharpe, and Dohme’s type 2 diabetes drug Steglatro in a final decision, after the company undercut rivals from the same class.